Loader

Pathways

PathWhiz ID Pathway Meta Data

PW121840

Pw121840 View Pathway
disease

Ribose-5-phosphate Isomerase Deficiency

Mus musculus
Ribose-5-phosphate isomerase (RPI) deficiency, is a genetic disorder caused by mutations in the RPIA gene that codes for RPI. RPI is an enzyme that is involved in the pentose phosphate pathway as part of carbohydrate degradation. It reversibly converts D-ribulose 5-phosphate into D-ribose 5-phosphate. In the case of this disorder, RPI functions partially in tissues, because if the gene was simply non-functional, it would likely be lethal. This means that a specific type of mutation needs to occur for this disorder to occur, leading to it being the rarest disease in the world, with only three confirmed cases. In the first known case, the patient had one allele containing a frameshift mutation, which led to a truncated protein, while the other allele contained a missense mutation. This combination meant that activity of RPI was found to vary across tissues and cell types. Characteristics of the RPI deficiency include higher ribitol and arabitol levels in a metabolic profile, as well as differences in polyol profiles. There are other symptoms, including leukoencephalopathy and neuropathy, which may be caused by a toxic accumulation of ribitol and arabitol, or a potential lack of ribose-5-phosphate in RNA synthesis.

PW000495

Pw000495 View Pathway
disease

Ribose-5-phosphate Isomerase Deficiency

Homo sapiens
Ribose-5-phosphate isomerase (RPI) deficiency, is a genetic disorder caused by mutations in the RPIA gene that codes for RPI. RPI is an enzyme that is involved in the pentose phosphate pathway as part of carbohydrate degradation. It reversibly converts D-ribulose 5-phosphate into D-ribose 5-phosphate. In the case of this disorder, RPI functions partially in tissues, because if the gene was simply non-functional, it would likely be lethal. This means that a specific type of mutation needs to occur for this disorder to occur, leading to it being the rarest disease in the world, with only three confirmed cases. In the first known case, the patient had one allele containing a frameshift mutation, which led to a truncated protein, while the other allele contained a missense mutation. This combination meant that activity of RPI was found to vary across tissues and cell types. Characteristics of the RPI deficiency include higher ribitol and arabitol levels in a metabolic profile, as well as differences in polyol profiles. There are other symptoms, including leukoencephalopathy and neuropathy, which may be caused by a toxic accumulation of ribitol and arabitol, or a potential lack of ribose-5-phosphate in RNA synthesis.

PW127878

Pw127878 View Pathway
drug action

Ribostamycin Action Pathway

Homo sapiens
Ribostamycin is a broad-spectrum antibiotic on the list of WHO critical antimicrobials for human medicine. This drug is in the aminoglycosides antibiotic family. This is isolated from the bacteria called Streptomyces ribosidificus. Ribostamycin works by binding to the bacterial 30S ribosomal subunit, inhibiting the translocation of the peptidyl-tRNA from the A-site to the P-site and also causing misreading of mRNA. With this binding, the bacteria are unable to synthesize vital proteins for its growth. However, their exact mechanism of action is not fully known.

PW145536

Pw145536 View Pathway
drug action

Ribostamycin Drug Metabolism Action Pathway

Homo sapiens

PW124263

Pw124263 View Pathway
protein

Rice

Oryza sativa subsp. japonica

PW131001

Pw131001 View Pathway
metabolic

Rice bran Drug Metabolism

Homo sapiens

PW144730

Pw144730 View Pathway
drug action

Rifabutin Drug Metabolism Action Pathway

Homo sapiens

PW176401

Pw176401 View Pathway
metabolic

Rifampicin Predicted Metabolism Pathway

Homo sapiens
Metabolites of Rifampicin are predicted with biotransformer.

PW147013

Pw147013 View Pathway
metabolic

Rifampin Drug Metabolism Pathway

Homo sapiens

PW146444

Pw146444 View Pathway
drug action

Rifamycin Drug Metabolism Action Pathway

Homo sapiens